Strong hint towards Amgen licensing a bisantrene+carfilzomib coformulation (that we hold the patent for) here. I love it.
More and more I see the pieces coming together for a series of license-based transactions and partnerships by cancer indication. Cash, royalties, biobux, then a major transaction down the line.
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.015(1.28%) |
Mkt cap ! $201.5M | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.15 | $43.72K | 37.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4346 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 2188 | 1 |
View Market Depth
| Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |